RBDCOV: COVID-19 vaccine trial in people with immunocompromising conditions has been launched in Turkey

Back to the "News" list

The clinical trial of HIPRA’s COVID-19 vaccine in people with immunocompromising conditions has now been launched in the Turkish sites.


The Turkish Clinical Study will aim to involve 60 volunteers from three hospitals in Turkey: two in Ankara (Ankara University Medical Faculty Hospitals and Hacettepe University Medical Faculty Hospitals) and one in Istanbul (Koç University Hospital).


The aim of the study is to discover whether or not HIPRA’s vaccine is able to reactivate or re-generate a sufficient immune response and increase the activity of the immune system (natural defenses) to SARS-CoV-2.


As you know, EATG is participating in the RBDCOV project, one of the 11 selected projects supporting clinical trials for a new vaccine that can go beyond Europe’s borders. This project is funded by the Horizon Europe Framework Programme (2021-2027).


Find more information about the initiation of the first clinical trial of RBDCOV in this press release.


The RBDCOV project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101046118

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?


Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.